GlassScriptPhysician profile
Ching Hai Chang
NPI 1174545909
$5,261.17
in general payments reported to CMS, 2019-2025
32 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $89.99 · 2021: $1,132 · 2022: $774 · 2023: $1,052 · 2024: $938 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.24 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $897.76 | 2019-2025 | |
| Abbvie INC. | $821.60 | 2019-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $672.31 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $445.52 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $379.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.50 | 2019-2025 | Jardiance |
| Amgen INC. | $283.40 | 2022-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $237.80 | 2020-2022 | |
| Novo Nordisk INC | $165.28 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $145.96 | 2022 | |
| Bausch Health US, LLC | $139.56 | 2021-2025 | Aplenzin, Wellbutrin |
| Astellas Pharma US INC | $125.29 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $69.91 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.21 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $61.14 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $51.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $43.66 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $34.33 | 2021-2025 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $32.80 | 2019 | |
| Aimmune Therapeutics, INC. | $32.57 | 2025 | Zenpep |
| Dexcom, INC. | $26.64 | 2021 | |
| Abbott Laboratories | $25.50 | 2024 | Freestyle Libre 3 |
| Eisai INC. | $25.27 | 2025 | |
| Vanda Pharmaceuticals INC. | $24.44 | 2024 | Hetlioz, Fanapt |
| Pulmonx Corporation | $23.42 | 2019 | |
| Gilead Sciences, INC. | $22.99 | 2025 | |
| Idorsia Pharmaceuticals US INC | $21.62 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $21.32 | 2021 | |
| Cequr Corporation | $16.43 | 2023 | Cequr Simplicity |
| Amarin Pharma, INC. | $16.11 | 2021 | |
| Currax Pharmaceuticals LLC | $15.35 | 2023 | Contrave |
| Sanofi Pasteur INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.